Free Trial

NLS Pharmaceutics (NLSP) Competitors

NLS Pharmaceutics logo
$2.32 +0.05 (+2.20%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.35 +0.03 (+1.25%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NLSP vs. ANVS, PLUR, MDCX, KPTI, EGRX, ACRV, PEPG, AKTX, XCUR, and BRNS

Should you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Annovis Bio (ANVS), Pluri (PLUR), Medicus Pharma (MDCX), Karyopharm Therapeutics (KPTI), Eagle Pharmaceuticals (EGRX), Acrivon Therapeutics (ACRV), PepGen (PEPG), Akari Therapeutics (AKTX), Exicure (XCUR), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry.

NLS Pharmaceutics vs. Its Competitors

NLS Pharmaceutics (NASDAQ:NLSP) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

NLS Pharmaceutics' return on equity of 0.00% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
NLS PharmaceuticsN/A N/A N/A
Annovis Bio N/A -300.56%-193.50%

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 1 articles in the media. NLS Pharmaceutics' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NLS Pharmaceutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Annovis Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

NLS Pharmaceutics has a beta of 0.18, indicating that its share price is 82% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NLS PharmaceuticsN/AN/A-$1.98MN/AN/A
Annovis BioN/AN/A-$24.59M-$2.16-1.17

15.8% of Annovis Bio shares are owned by institutional investors. 16.4% of NLS Pharmaceutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Annovis Bio has a consensus target price of $18.00, indicating a potential upside of 611.46%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than NLS Pharmaceutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NLS Pharmaceutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Annovis Bio
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

Annovis Bio beats NLS Pharmaceutics on 7 of the 10 factors compared between the two stocks.

Get NLS Pharmaceutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NLSP vs. The Competition

MetricNLS PharmaceuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.17M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.04%
P/E RatioN/A8.9826.9620.11
Price / SalesN/A729.50430.20119.79
Price / CashN/A159.8036.8257.86
Price / Book-6.274.517.985.56
Net Income-$1.98M$31.26M$3.16B$248.40M
7 Day Performance-9.73%3.57%2.39%4.67%
1 Month Performance-15.64%1.28%2.18%6.64%
1 Year Performance1,221.94%1.08%33.82%21.31%

NLS Pharmaceutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NLSP
NLS Pharmaceutics
N/A$2.32
+2.2%
N/A+1,192.5%$8.17MN/A0.006
ANVS
Annovis Bio
1.4865 of 5 stars
$2.18
+6.3%
$30.25
+1,287.6%
-83.6%$39.95MN/A-1.013
PLUR
Pluri
3.5399 of 5 stars
$4.95
-2.8%
$12.00
+142.4%
-3.8%$39.87M$330K-0.90150Positive News
Gap Down
MDCX
Medicus Pharma
2.53 of 5 stars
$2.99
+3.1%
$23.50
+686.0%
N/A$39.36MN/A-2.58N/ANews Coverage
Upcoming Earnings
Gap Up
KPTI
Karyopharm Therapeutics
3.8168 of 5 stars
$4.31
-1.8%
$43.20
+902.3%
-60.8%$37.93M$145.24M-0.32380
EGRX
Eagle Pharmaceuticals
N/A$2.90
+7.4%
N/A-45.9%$37.66M$257.55M0.00100
ACRV
Acrivon Therapeutics
2.3371 of 5 stars
$1.19
-0.8%
$17.71
+1,388.6%
-81.5%$37.63MN/A-0.5458
PEPG
PepGen
2.9105 of 5 stars
$1.11
-3.5%
$7.67
+590.7%
-93.1%$37.63MN/A-0.3530
AKTX
Akari Therapeutics
1.3216 of 5 stars
$1.17
+0.9%
N/A-61.1%$37.30MN/A0.009
XCUR
Exicure
1.3424 of 5 stars
$7.04
+19.5%
N/A+2,197.5%$37.21M$500K-1.8450Gap Up
High Trading Volume
BRNS
Barinthus Biotherapeutics
2.5496 of 5 stars
$0.93
+1.5%
$6.25
+572.0%
-31.1%$36.95M$14.97M-0.57107News Coverage

Related Companies and Tools


This page (NASDAQ:NLSP) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners